Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Reyvow™ (lasmiditan) – New drug approval
October 11, 2019 - The FDA announced the approval of Eli Lilly’s Reyvow (lasmiditan), for the acute treatment of migraine with or without aura in adults.
